Expert guides, hospital insights, and medical travel tips for your China health journey
On January 2, 2025, China's NMPA approved its first-ever mesenchymal stem cell therapy. Here's what the science actually says — and what it means for patients.
China now runs more CAR-T clinical studies than any other country, including the United States. We break down the published outcomes data for international oncology patients.
In March 2025, Shanghai's Ruijin Hospital performed China's first GCP-standard iPSC cell transplant for Parkinson's disease. The 6-month results are published — here's an honest look.
A study covering 6.4 million cancer patients across all 32 Chinese provinces published updated 5-year survival data. We break down what it says — and where China excels versus the West.
China ranks 5th globally in JCI-accredited hospitals. A published study examined the actual impact of accreditation on clinical and financial performance — here's what it found.
300,000 patients visited Boao Lecheng in 2023. 28,000 accessed drugs not yet approved for mainland China. Here's how the zone actually works — and what treatments are available.
A meta-analysis of 62 studies involving 2,439 spinal cord injury patients examined stem cell therapy outcomes. The data is more nuanced than the headlines — here's what it actually shows.
1,795 Grade-A hospitals. A life expectancy now ranking above 21 high-income countries. USD 1.25 trillion in health spending. The scale of China's healthcare system is often misunderstood.
China is now the world's second-largest producer of orthopedic robotic surgery research. A 2024 meta-analysis of 17 studies and 1,741 patients examined Chinese robotic systems — here's what it found.
China's regenerative medicine market hit USD 980 million in 2023 and is projected to reach USD 2.57 billion by 2030. Behind the market figures is a genuine clinical expansion — here's what's driving it.
Everything international patients need to know about accessing stem cell therapy in China — regulatory status, available treatments, costs, and how to identify legitimate providers.
China leads global MSC clinical trials for autoimmune diseases. We analyze published outcomes from lupus, Crohn's, and rheumatoid arthritis studies at top Chinese research hospitals.
China has overhauled its stem cell regulatory framework since 2021. Understanding the new NMPA rules is essential for any patient considering treatment in China.
Human umbilical cord mesenchymal stem cells (hUC-MSCs) are the foundation of China's stem cell medicine sector. Here's what the science says about how they work and why they're preferred.
For ALS patients and those with spinal cord injuries, China's active neurological stem cell trials offer options not available elsewhere. Here's an honest assessment of the evidence.
Anti-aging stem cell clinics are among the most aggressively marketed offerings in Asia. Here's what the evidence actually shows — and what patients should be cautious about.
China has published some of the strongest clinical data globally on stem cell therapy for cartilage defects and knee osteoarthritis. Here's what the trials show and who is eligible.
China's stem cell clinical trials include significant programs targeting Type 1 diabetes, Type 2 diabetes complications, and liver cirrhosis. We review what the published data shows.
Not all stem cell providers in China operate to the same standard. This guide gives patients a concrete due diligence framework for evaluating any Chinese stem cell hospital or clinic.
From trial volumes to published research output and regulatory milestones, here is a data-driven assessment of where China stands in the global stem cell research landscape.
China has deployed AI-assisted cancer screening at a scale few countries can match. Here is what the technology landscape looks like — and why it matters for international patients.
China is now the world's second-largest hub for AI-driven drug discovery, with dozens of dedicated companies and multiple candidates in clinical trials. Here's what the pipeline looks like in 2025.
China's NMPA has approved over 280 AI medical imaging products. Here is how they are being used in hospitals — and what the real-world evidence shows about performance.
China's Precision Medicine Initiative and BGI's genomic sequencing network have created datasets that AI systems are translating into clinical insights. Here's what that means in practice.
China is using AI to decode the pharmacology of traditional herbal medicine, standardize TCM diagnosis, and bring evidence-based rigor to an ancient practice. The results are genuinely interesting.
China is digitizing pathology at scale. AI systems evaluated at Chinese cancer centers are matching specialist pathologist performance in several cancer types — with implications for diagnostic access.
China has developed six domestically approved surgical robot platforms to challenge da Vinci's dominance. Here is what the clinical evidence shows — and why cost matters for international patients.
Chinese ICUs are implementing AI early warning systems that identify patients at risk of sepsis and deterioration earlier than conventional clinical assessment. Here is what the evidence shows.
China faces a severe mental health workforce shortage. AI-powered screening and chatbot support tools are being deployed at scale — here is what the published evidence actually shows about their effectiveness.
Chinese hospitals handled 3.19 billion outpatient visits in 2023. AI queue management, triage, and administrative automation are the tools enabling this scale — here is how they work.
Panda Touring Care Newsletter
Research-backed guides on stem cell therapy, hospital quality data, and medical travel — delivered weekly.
No spam, ever. Unsubscribe anytime.